1

Teva introduction

2013

Established by three young pharmacists, selling drugs in a small store

Starting out at 1901 in Jerusalem

More than a century later

We are among the top 10 pharmaceutical companies and a world leader in Generics

Our Vision

Being the most indispensable

medicines company for the world,

executing on our obligation to

our patients, customers,

shareholders and employees

We have Profound Foundations

45,000 employees

73 manufacturing

sites

111 years in

existence

1,000 molecules

60 countries

73B tablets and

capsules per annum

55,000+ SKUs

$5.01 2013 EPS

$20.3B 2013 revenues

Core Strengths

Leading healthcare provider

Balanced business

model

Integrated

R&D

Manufacturing strengths

Partnering experience

Go-to-market capabilities

Entrepreneurial employees and

culture

Growth drivers

CNS Respiratory High-value generics NTEs (New therapeutic entity)

MS PD Oncology Respiratory Women’s Health Branded generics High-value generics

OTC (over the counter)

MS Branded generics

Branded generics Respiratory Women’s Health MS OTC (over the counter)

MS Generics Branded generics

A truly global operations network

Financial Growth

2013 2012

20,314 20,317 Sales $M

5,198 5,715 Operating Income $M

4,255 4,671 Net Income $M

* Operating income and net income are non-GAAP results

Expansion of wealth and health care access

Rising health care costs

Our World Changes

Aging population

Increasing competition in generics

Shift in disease patterns

Rising bar for product innovation

Complicated, expanding global market

Complexity

Cost

Network footprint

Commodity

The new Teva

Less More

Globalized

Valuable pipeline

Sustainable products

Patient and customer focus

Balanced profits

Shareholder value

Teva 2017: a reshaped company

Sector leadership in all areas

Sustainable profitable growth

Present in all major markets

Consistent shareholder value creation

Successful alliances

Rich Pipeline

Branded generics business

R&D capabilities

Impact healthcare system

Pipeline of high-value products

Generics: a great future

Global

Sustainable high-barrier to entry

Rapid growth

Dramatically enhanced in selected areas

Research and development

Develop the most competitive

and focused pipeline

to address unmet patient needs

in a highly differentiated way

to drive the growth of Teva

Life and science intimately connected … that’s uniquely Teva

NTEs High value

generics

Focused specialty portfolio

NTEs - The Future of Teva R&D

NEW THERAPEUTIC ENTITY Known molecule that is formulated, delivered, or used in a novel way to

address specific patient needs

Specialty medicines: focus and build leadership

CNS

Respiratory

New Therapeutic Entities (NTEs)

Oncology, Women's Health, Biologics

Protect and expand MS franchise

Build products and pipeline

Invest in capabilities and pipeline

Continue global expansion

Capitalize on unique Teva interface

of Generics and Specialty

Selectively invest

17 17

OTC Business

World’s leading provider of medicines Portfolio of leading brands

Best-in-class

Consumer understanding

Brand-building

Advertising scale

Strong product development and

production capabilities World’s leading brand-

builder

+

PGT Consumer Healthcare: JV with P&G leverages value in existing OTC business

18

Our Guiding Values

Our Guiding Values represent an unbreakable chain of behaviors ...

and a process that embodies the very nature of how we operate …

at the heart of Teva.

19

Our Storyline

At the heart of Teva, we believe that:

Individual Integrity drives mutual Respect …

Mutual Respect leads to healthy Collaboration …

Healthy Collaboration powers our pursuit of Excellence …

Our pursuit of Excellence is key to Teva’s ongoing Leadership …

… and ongoing Leadership depends upon our individual Integrity.

20